The aging prostate is never "normal": implications from the genomic characterization of multifocal prostate cancers.
We argue against the recently published statement that tumor-specific molecular alterations found in "normal" prostate tissue from cancer patients challenge focal therapy approaches that only target a visible cancer lesion and not the adjacent molecular field.